of phospholipase A 2 (PLA 2 ) and yields deleterious effects on heart muscle (12, 13) . In rat kidneys, reperfusion leads to an elevation of LPC, free fatty acids, diacyl glycerol, and phosphatidic acid (20) . Persistent elevation of these levels correlated with injury and, when applied to primary explants of proximal tubule cells, leads to cell disruption via damage to the plasma membrane. These multiple divergent responses are likely mediated by specific LPA receptors that have distinct signaling mechanisms. The high concentration of LPC in plasma and serum suggests that local production of LPA could evoke an inflammatory response that may play a significant role in ischemiareperfusion (I/R) injury.
We took advantage of recent advances in the pharmacology and molecular biology of LPA receptors to determine whether LPA receptors are involved I/R injury. Our results highlight a potential role of LPA 3 receptors in mediating injury and a potential novel target for therapeutic intervention.
METHODS
Renal ischemia surgical protocol. C57BL/6 mice (7-8 wk of age, Hilltop Laboratory Animals, Scottsdale, PA) were allowed free access to food and water until the day of surgery. Mice were anesthetized with a regimen that consisted of ketamine (100 mg/kg ip), xylazine (10 mg/kg ip), and acepromazine (1 mg/kg im) and were placed on a thermoregulated pad to maintain body temperature at 37°C. Both renal pedicles were identified and cross-clamped for 27-32 min. On release of the clamps, the kidneys were observed for reperfusion. Surgical wounds were closed, and mice were returned to cages for up to 24 h. At the end of the experimental period, animals were reanesthetized, blood was obtained by cardiac puncture, and kidneys were removed for various analyses.
Compound administration. A 1 mM stock solution of 1-oleoyl LPA (18:1 LPA), VPC-12249, or oleoyl-methoxy phosphothionate (OMPT) was prepared in a 3% fatty acid-free bovine serum albumin/PBS solution (Sigma, St. Louis, MO). Two protocols were followed for drug administration. For dose-response experiments (0.01, 0.1, and 1.0 mg ⅐ kg Ϫ1 ⅐ dose Ϫ1 ), vehicle (3% fatty acid-free bovine serum albumin/ PBS solution), 18:1 LPA, VPC-12249, or OMPT was administered every 2 h beginning 2 h before ischemia and continu-ing for an additional four doses. A second protocol was followed to determine whether delayed treatment altered the efficacy of VPC-12249. In this second protocol, the compound administration was initiated 0.5, 1.0, or 1.5 h after the onset of reperfusion and was continued every 2 h for four additional doses.
Tail cuff blood pressure and heart rate measurement. Systolic blood pressure and heart rate were measured by using a photoelectric sensor for pulse detection in mouse tail (IITC model 179, IITC/Life Science Instruments, Woodland Hills, CA). Mice were allowed to rest quietly for 10 min in a chamber with the temperature controlled at 26°C. Blood pressures were measured twice and averaged. Measurements were made at baseline before compound administration, 30 and 60 min after intraperitoneal injection.
Plasma creatinine measurement. Plasma creatinine concentrations were determined using a colorimetric assay according to the manufacturer's protocol (Sigma).
Myeloperoxidase activity. Myeloperoxidase (MPO) activity was determined in kidney homogenates (25) . Kidneys were harvested from mice subjected to the I/R protocol, and a portion of the kidney was snap-frozen in liquid N 2 until time of assay. Kidneys were homogenized in 10 vol of ice-cold 50 mM potassium phosphate buffer, pH 7.4, using a Tekmar tissue grinder. The homogenate was centrifuged at 15,000 g for 15 min at 4°C, and the resultant supernatant was discarded. The pellet was washed twice, resuspended in 10 vol of ice-cold 50 mM potassium phosphate buffer with 0.5% hexadecyltrimethylammonium bromide, and sonicated. The suspension was subjected to three freeze/thaw cycles, sonicated for 10 s, and centrifuged at 15,000 g for 15 min at 4°C. The supernatant was added to an equal volume of a solution consisting of o-dianisidine (10 mg/ml), 0.3% H 2O2, and 45 mM potassium phosphate, pH 6.0. Absorbance was measured at 460 nm over a period of 5 min (1).
Histology. Kidneys were fixed in periodate-lysine-paraformaldehyde (4% paraformaldehyde) and embedded in paraffin, and 4-m sections were cut. Sections were subjected to routine staining with hematoxylin and eosin (H and E) and viewed by light microscopy (Zeiss AxioSkop). We quantified the degree of tubular necrosis using a semiquantitative index of H and E-stained tissue sections. Sections were viewed in a masked fashion (MDO) under ϫ400 magnification, and the percentage of tubules showing epithelial necrosis was assigned the following scoring system: 0 ϭ normal; 1 ϭ Ͻ10%; 2 ϭ 10-25%; 3 ϭ 26-75%; 4 ϭ Ͼ75%. Five to 10 fields from each of the cortex, outer medulla, and inner medulla were evaluated, scored, and averaged. Some sections were stained with napthol-AS-D chloroacetate (Sigma) to localize neutrophils (19, 25) .
Immunohistochemistry. Sections were subjected to immunohistochemistry using methods previously described (24) . We used a rat monoclonal antibody to mouse neutrophils (Clone 7/4, Burlingame, CA). Sections were incubated with primary antibody (2 g/ml) followed by a biotinylated goat anti-rat secondary antibody. A peroxidase reaction was performed according to the manufacturer's protocol (Vectastain ABC Elite kit). Sections were viewed using a Zeiss AxioSkop microscope, and digital images were taken using a SPOT RT Camera (software version 3.3; Diagnostic Instruments, Sterling Heights, MI). Images were imported into Adobe Photoshop (3.0) where brightness/contrast was adjusted.
RNA isolation and cDNA synthesis. Kidneys were harvested from mice following reperfusion for 24 h. The capsule was removed, and kidneys were placed immediately in RNA- Fig. 1 . Lysophingolipid receptor mRNA expression in kidney. Kidney mRNA was analyzed by the PCR (see METHODS). Briefly, a PCR master mix consisted of PCR buffer, primer, and each primer and Platinum Taq DNA Polymerase. The mixture was subjected to initial melting (95°C for 3 min) followed by 38 successive cycles of denaturation, annealing, and elongation (95°C for 45 s, 59.5°C for 60 s, 72°C for 60 s), then a final elongation step (72°C for 7 min) and a holding step at 4°C. Arrows indicate appropriate size amplification product for lysophosphatidic acid (LPA1), LPA2, and LPA3 receptor mRNA. Also shown are amplification products for sphingosine 1-phosphate (S1P) receptor mRNAs. Primer composition and predicted sizes of amplification products can be found in Table 1 . later (Ambion, Austin, TX) and stored at Ϫ70°C until RNA preparation. Total RNA was extracted from whole kidney or cortex, outer medulla, and inner medulla tissue using the Ultraspec RNA Isolation System according to the manufacturer's protocol (Biotecx Laboratories, Houston, TX). cDNA was synthesized from the total RNA isolated from the cortex, outer medulla, and inner medulla tissue using the ThermoScript RT-PCR System according to the manufacturer's protocol (Invitrogen, Life Technologies, Carlsbad, CA).
RT-PCR.
The presence of LPA 1, LPA2, and LPA3 receptor mRNAs in the cortex, outer medullary, and inner medullary tissue was confirmed via RT-PCR. RT-PCR was performed on the cDNA using the ThermoScript RT-PCR System with Platinum Taq DNA Polymerase according to the manufacturer's protocol (Invitrogen, Life Technologies). PCR oligonucleotide primers (Table 1) were designed using the software package Primer Select (Lasergene, DNASTAR, Madison, WI). The following PCR protocol was used: initial denaturation (95°C for 3 min), denaturation, annealing, and elongation program repeated 38 times (95°C for 45 s, 59.5°C for 60 s, 72°C for 60 s), final elongation (72°C for 7 min), and finally a holding step at 4°C.
Quantitative real-time PCR. Quantitative real-time PCR was performed on the cDNA from the cortex, outer medullary, and inner medullary tissue using the QuantiTect SYBR Green PCR Kit according to the manufacturer's protocol (Qiagen, Valencia, CA). PCR oligonucleotide primers (Table  1) were designed using the software package Primer Select (Lasergene, DNASTAR). The PCR master mix was prepared by combining the following reagents to the indicated end ) beginning 2 h before ischemia followed by additional doses every 2 h for 4 additional doses. Values are means Ϯ SE; n ϭ 4 for each group. *P Ͻ 0.001 compared with vehicle. 18:1 LPA (1.00 mg ⅐ kg Ϫ1 ⅐ dose Ϫ1 ) was not significantly different from vehicle. Fig. 3 . Effect of oleoyl-methoxy phosphothionate (OMPT), a selective LPA3 agonist on renal I/R injury. A: Mouse kidneys were subjected to 32 min of ischemia followed by 24-h reperfusion. After reperfusion, mice were killed and blood was obtained for measurement of plasma creatinine. Mice were treated with vehicle or OMPT (0.01, 0.1, and 1 mg ⅐ kg Ϫ1 ⅐ dose Ϫ1 ) beginning 2 h before ischemia followed by 4 additional doses every 2 h. Values are means Ϯ SE; n ϭ 4-5 for each group. B: mouse kidneys were subjected to 27 min of ischemia followed by 24-h reperfusion. Mice were treated with vehicle (n ϭ 8) or OMPT (1.0 mg ⅐ kg Ϫ1 ⅐ dose
Ϫ1
; n ϭ 8) beginning 2 h before ischemia followed by 4 additional doses every 2 h. Values are means Ϯ SE. *P Ͻ 0.02. Values are means Ϯ SE and represent the ratio of cycle number to reach an arbitrary fluorescence intensity of the sample relative to GAPDH. Each reaction was performed in duplicate, and values were averaged. In some cases, only a single value was available for a given reaction. Numbers in parentheses represent numbers of mice. NS, not significant.
concentrations and the final volume of 50 l: 1ϫ QuantiTect SYBR Green PCR Master Mix, 0.3 M forward primer, 0.3 M reverse primer ( Table 1 ). The PCR master mix was combined with 2 l cDNA (1 g reverse-transcribed total RNA) in a 96-well PCR Plate for iCycler iQ (Bio-Rad Laboratories, Hercules, CA) and subsequently covered with Optical Quality Sealing Tape for iCycler iQ (Bio-Rad Laboratories). The PCR plate was centrifuged and placed in the iCycler iQ Real-Time Detection System (Bio-Rad Laboratories). The following PCR protocol was used: denaturation program (95°C for 13 min), amplification and quantification program repeated 45 times (94°C for 30 s, 56°C for 30 s, 72°C for 30 s with a single fluorescence measurement), melting curve program (55-95°C with a heating rate of 0.5°C per 10 s and a continuous fluorescence measurement), and finally a cooling step to 20°C. The data generated were analyzed by iCycler iQ Real-Time Detection System software (Bio-Rad Laboratories). A threshold value of 10 times the mean standard deviation of fluorescence in all wells over the baseline cycles was calculated. This threshold is located in the region of exponential amplification of all samples. The number of cycles required for a sample to cross this threshold was compared with the number of cycles required for GAPDH to cross the threshold. These ratios were plotted and compared. Each sample was run in duplicate.
Statistical analysis. A randomized block design was used to analyze the data. In this design, we considered the day of the procedure as a blocking factor. This is done to minimize variables that may affect our comparisons. We typically perform experiments in which a small group of mice (experimental and treatment group) is subjected to I/R injury on the same day. ANOVA and post hoc analysis (Bonferroni or Dunnett) were performed. In some analyses, unpaired Student's t-tests were used. P Ͻ 0.05 was used to determine significance.
RESULTS
LPA and sphingosine 1-phosphate receptor mRNA expression in mouse kidneys. The family of Edg receptors was first examined to determine the expression of LPA and sphingosine 1-phosphate (S1P) receptor mRNA in kidneys. Table 1 lists primers used to amplify LPA and S1P receptor mRNA from mouse kidneys. LPA 1 , LPA 2 , and LPA 3 mRNA were detected in whole mouse kidney mRNA (Fig. 1) . Furthermore, S1P 1 , S1P 2 , and S1P 3 mRNA were expressed in mouse kidney; however, S1P 4 and S1P 5 mRNA were not found in mouse kidneys. The results of quantitative real-time PCR of LPA receptor mRNA in kidney are shown in Table 2 . The abundance of LPA receptors relative to GAPDH was in the following order LPA 3 ϭ LPA 2 Ͼ LPA 1 in the cortex, outer medulla, and inner medulla.
Effect of LPA agonists on I/R. Initially, we sought to determine the effect of LPA on I/R injury. A nonselec- 
Values are means Ϯ SE. NS, not significant. tive LPA agonist, 18:1 LPA, was administered 2 h before I/R injury followed by four subsequent doses every 2 h for four additional doses. As shown in Fig. 2 , 18:1 LPA at the lower doses produced a modest degree of protection. Plasma creatinine values for vehicle, 0.01-and 0.1-mg/kg dosages, were 2.37 Ϯ 0.81, 1.37 Ϯ 0.17 (58% of vehicle; P Ͻ 0.001), and 1.06 Ϯ 0.63 mg/dl (45% of vehicle; P Ͻ 0.001), respectively. This protective effect was lost at the highest dose, i.e., the plasma creatinine was 1.51 Ϯ 0.17 mg/dl (64% of vehicle; not significant) at a dosage of 1 mg/kg.
Eighteen-to-one LPA is more potent at the LPA 1 and LPA 2 receptors compared with the LPA 3 receptor, suggesting a lower affinity for the latter site (2). The loss of significant protection from I/R injury at the highest dose of 18:1 LPA suggested the possibility that LPA receptors may have different functional effects. Eighteen-to-one LPA has an apparent lower affinity for LPA 3 receptors, thus the highest dosage may have activated this receptor and negated the beneficial effects observed at lower doses. To test this hypothesis, we next used OMPT, a highly selective LPA 3 receptor agonist (10) . Mouse kidneys were subjected to 32 min of ischemia followed by 24 h of reperfusion, and OMPT was administered 2 h before I/R followed by four additional doses every 2 h beginning at the onset of reperfusion. Unlike 18:1 LPA, OMPT did not exert a protective effect at any dose tested; indeed, this LPA 3 receptor-selective agonist appeared to aggravate injury at the 0.1-mg/kg dose (Fig. 3A) . At this dose, plasma creatinine following I/R injury was 133% of vehicle treatment; however, this difference was not significant. We reasoned that the high-grade injury induced by 32 min of ischemia may have prevented our observing a higher degree of injury with OMPT. To test this idea, we repeated the experiment, reducing the degree of ischemia by shortening the time from 32 to 27 min. With this protocol, we found that OMPT (0.1 mg ⅐ kg Ϫ1 ⅐ dose Ϫ1 ) produced significant injury compared with vehicle (Fig. 3B) . Plasma creatinine was 0.39 Ϯ 0.05 (n ϭ 8) and 0.92 Ϯ 0.17 mg/dl (n ϭ 6) (P Ͻ 0.02) for vehicle and OMPT, respectively. These results suggest that LPA receptors have multiple functional effects and that LPA 3 receptor activation might enhance I/R injury.
Dual LPA 1 /LPA 3 antagonist reduced renal I/R injury. We next performed a series of experiments to determine the effect of blocking LPA 3 receptors on I/R injury. For these experiments, we used VPC-12249, a dual LPA 1 /LPA 3 antagonist (14) . Mouse kidneys were subjected to 32 min of ischemia/24 h reperfusion and treated with vehicle or VPC-12249 (0.01, 0.1, and 1.0 mg ⅐ kg Ϫ1 ⅐ dose Ϫ1 ) (Fig. 4A) . Whereas vehicle treatment led to a marked increase in plasma creatinine (1.49 Ϯ 0.26 mg/dl), VPC-12249 at 0.01, 0.1, and 1.0 mg ⅐ kg Ϫ1 ⅐ dose Ϫ1 led to a dose-dependent decrease in plasma creatinine of 1.06 Ϯ 0.25 (71% of vehicle; not significant), 0.45 Ϯ 0.125 (45% of vehicle; P Ͻ 0.05), and 0.31 Ϯ 0.04 mg/dl (21% of vehicle; P Ͻ 0.01), respectively, compared with control.
To determine whether delaying administration until after the start of the reperfusion period can protect kidneys from injury, we administered vehicle or VPC-12249 120 min before ischemia as well as 30, 60, and 90 min after the onset of reperfusion (Fig. 4B ). This figure shows that the fractional reduction of plasma is greatest when VPC-12249 is administered 2 h before ischemia. Compared with vehicle treatment, plasma creatinine (fractional change) was reduced by 0.75 Ϯ 0.09. A similar reduction of plasma creatinine was observed when VPC-12249 was delayed by 30 min. In this case, the fractional change was 0.56 Ϯ 0.09, which was not significantly different from the 75% reduction observed when VPC-12249 was administered 2 h before ischemia. However, when VPC-12249 was delayed 1 and 1.5 h, the fractional reduction of plasma creatinine compared with vehicle treatment was 0.22 Ϯ 0.16 (P Ͻ 0.05) and 0.27 Ϯ 0.122 (P Ͻ 0.05). These fractional reductions in plasma creatinine were significantly less than when VPC-12249 was administered 2 h before ischemia.
Protective effect of VPC-12249 on mice subjected to renal I/R injury is mediated by LPA 3 receptors. To determine whether the protective effect of VPC-12249 was due to blockade of LPA 3 and/or LPA 1 receptors, we coadministered OMPT and VPC-12249 (Fig. 5) . We performed renal I/R in mice treated with vehicle, VPC-
) ϩ VPC-12249. Plasma creatinine following 32 min of ischemia/24 h reperfusion was 1.51 Ϯ 0.21 (n ϭ 4), 0.36 Ϯ 0.11 (24% of vehicle; n ϭ 4; P Ͻ 0.01), and 0.99 Ϯ 0.17 mg/dl (66% of vehicle; n ϭ 4; not significant) for vehicle, VPC-12249, and OMPT ϩ VPC12249. These results suggest that the protective effect of VPC-12249 was mediated, in large part, by blocking LPA 3 receptors.
VPC-12249 reduces tubular injury and ischemic necrosis following I/R injury in mice.
Light microscopic analysis of the outer medulla following I/R injury revealed a loss of brush-border villi, tubular necrosis, and obstruction of proximal tubule cells in outer medulla of vehicle-treated mice (Fig. 6C) . The severity of ) was administered intraperitoneally beginning 2 h before ischemia-reperfusion and subsequently for 4 additional doses. We quantified the degree of necrosis by assigning a value to the degree of renal injury based on the following scoring system from vehicle-and VPC-12249-treated mice: 0 ϭ normal, 1 ϭ Ͻ10%, 2 ϭ 10-25%, 3 ϭ 26-75%, and 4 ϭ Ͼ75% necrosis. Kidney tissue was viewed under ϫ400 magnification. Five to 10 fields from each of cortex, outer medulla, and inner medulla were evaluated, scored, and averaged. N ϭ 5 vehicle-treated and VPC-12249-treated mice. P values given for comparison of vehicle-to VPC-12249-treated mice were determined from unpaired t-tests.
the injury was reduced markedly in kidneys from mice treated with VPC-12249 (Fig. 6D) . Similar reduction of tissue injury was evident from the cortex and outer medullary (Fig. 6, A and B, vehicle and VPC-12249, respectively) and inner medullary (Fig. 6 , E and F, vehicle and VPC-12249, respectively) sections. Table 3 demonstrates injury quantitatively in the cortex, outer medulla, and inner medulla of kidneys. VPC-12249 reduced injury significantly in the outer medulla.
VPC-12249 reduces leukocyte infiltration in kidneys subjected to I/R injury in rats. Leukocytes are thought to contribute to renal injury following I/R, therefore we examined the degree of leukocyte infiltration by using MPO activity. We found that I/R injury produced an increase in MPO activity in mice following 24 h of reperfusion. VPC-12249 reduced kidney MPO activity; MPO activity was 1.50 Ϯ 0.10 (n ϭ 15) and 0.84 Ϯ 0.14 ⌬OD 460 ⅐ g Ϫ1 ⅐ min Ϫ1 at 24 h (n ϭ 15) in vehicle-and VPC-12249-treated mice, respectively (P Ͻ 0.005) (Fig.  7) . With the use of a stain for neutrophils, napthol AS-D choloracetate, or an anti-neutrophil antibody, we observed that neutrophils in vehicle-treated mice accumulated primarily in the peritubular capillaries of the outer medulla (Fig. 8, A and C) . VPC-12249 decreased neutrophil accumulation in this region (Fig. 8,  B and D) .
Effect of VPC-12249 and OMPT on blood pressure and heart rate. Alterations in systemic hemodynamics could contribute to the observed effect of VPC-12249 and OMPT; therefore, we measured blood pressure and heart rate at baseline and 30 and 60 min after intraperitoneal administration of vehicle, VPC-12249 (0.1
), or VPC-12249 ϩ OMPT. Blood pressure (Fig. 9A ) and heart rate ( Fig. 9B) were not affected by any of the treatment regimens at any of the time points.
DISCUSSION
We found that LPA had a paradoxical effect in our model of kidney I/R injury. That is, at lower doses, 18:1 LPA was protective, but this protection was lost at a higher dosage. However, when a LPA 3 receptor-selective agonist was substituted for 18:1 LPA, there was no protective effect at any dose; indeed, administration of this agonist exacerbated moderate injury. Interestingly, a LPA 3 -receptor antagonist reduced injury in a dose-dependent fashion and this protection was less- Fig. 7 . Effect of VPC-12249 on myeloperoxidase (MPO) activity of kidneys subjected to I/R. Mouse kidneys were subjected to 32-min ischemia followed by 24-h reperfusion. VPC-12249 (1 mg ⅐ kg Ϫ1 ⅐ dose
Ϫ1
) was administered intraperitoneally beginning 2 h before I/R followed by 4 additional doses every 2 h. MPO activity
) for vehicle (filled bar; n ϭ 15) or VPC-12249 treated (hatched bar; n ϭ 15). Values are means Ϯ SE. *P Ͻ 0.005. Fig. 8 . Effect of VPC-12249 on neutrophil accumulation in the outer medulla of kidneys subjected to I/R. Mouse kidneys were subjected to 32-min ischemia followed by 24-h reperfusion. Vehicle (A and C) or VPC-12249 (1 mg ⅐ kg Ϫ1 ⅐ dose
; B and D) was administered intraperitoneally beginning 2 h before I/R followed by 4 additional doses every 2 h. Kidneys were harvested, fixed, and embedded in paraffin. Four-micrometer sections were cut. Neutrophils were detected using napthol-AS-D chloroacetate (A and B) or an antineutrophil antibody (C and D). Arrowheads indicate neutrophils in peritubular capillaries of the outer medulla. Magnification ϫ400.
ened by collision with the LPA 3 receptor agonist. Because two LPA receptor types predominate in the kidney and one of these (LPA 2 ) appears to have a distinctly higher affinity than the other (LPA 3 ), we explain our results by ascribing a protective effect to agonist occupation of the LPA 2 receptor while agonist occupation of the other (LPA 3 ) receptor facilitates I/R injury. There is a biphasic effect of a nonselective agonist (i.e., 18:1 LPA) because protection occurs when the "protective" LPA receptor (LPA 2 ) is occupied, but this is reversed at increased doses as the LPA 3 receptor is occupied. The beneficial action of the antagonist is due to blockade of the "injury-promoting" receptor (LPA 3 ). This explanation predicts that a selective LPA 2 -receptor antagonist, were it available, would not be protective and might worsen injury.
Our conclusions are based on the binding characteristics of LPA, VPC-12249, and OMPT for LPA receptors. Several groups working in multiple systems (e.g., Sf9/baculovirus, Xenopus oocyte, HEK293 cells, broken cell [ 35 S]GTP␥S binding, etc.) showed consistently that the EC 50 values for LPA at LPA 3 are one to two log orders higher than those measured at the LPA 1 and LPA 2 receptors. 1 We interpret these data as meaning that the LPA 3 receptor is a low-affinity LPA binding site compared with the LPA 1 and LPA 2 receptors. However, some of the difference might be due to poorer coupling of the LPA 3 receptor to G proteins.
VPC-12249 behaves as a competitive antagonist, thus its binding affinity can be determined by Schild analyses; i.e., a radioligand binding assay is not required. The K i values so determined are LPA 1 ϭ 125 nM, LPA 2 Ͼ 5,000 nM, and LPA 3 ϭ 425 nM (22) . Note that although the affinity of LPA 3 for VPC-12249 is lower than that of LPA 1 , VPC-12249 might be a "better" blocker at LPA 3 , if we are correct in our assumption that this receptor has a lower affinity for LPA. A more subtle point is that the rank-order potency of 16:0 LPA and 18:1 LPA is different at various LPA receptors. For example, LPA 1 16:0 ϭ 18:1; LPA 2 16.0 ϭ 18:1; and LPA 3 16:0 Ͻ 18:1. Therefore, if the ischemic kidney produces 16:0 LPA preferentially over 18:1 LPA, VPC-12249 will be an even better blocker at the LPA 3 receptor site. Note that the two most prominent LPA species in serum are 16:0 and 18:1 LPA. Moreover, it should be noted that the expression of LPA 1 mRNA is barely detectable (Fig. 1 and Table 2 ), thus it is possible that LPA 1 receptors are expressed in a very low density. These data support our contention that VPC-12249 is a better blocker at LPA 3 than LPA 1 and LPA 2 .
OMPT is an agonist at LPA 3 ; in all assays, EC 50 for OMPT ϭ EC 50 for 18:1 LPA, whereas at the other two LPA receptors, OMPT ϽϽϽ LPA.
Our results are significant on several levels. First, our data extend an understanding of LPA actions in the kidney. In general, LPA has been viewed as a survival factor (5, 8, 15, 18, 21, 27) ; indeed, LPA treatment of primary cultures of dispersed mouse proximal tubule cells opposed apoptosis of these cells (18) . This concept is in line with our observation that lower doses of LPA are protective in the I/R injury model. Our present results suggest that LPA levels rise in the kidney during I/R injury. Although we do not have direct measurements of renal LPA levels, a related lipid and precursor of LPA, LPC, is reported to increase during injury (20) . Whether LPC or LPA is increased in other forms of renal injury is unknown. Furthermore, 1 Despite much effort by several groups, there is not yet a credible radioligand binding assay for LPA receptors. Therefore, we do not know affinity constants (Kd values) for agonist ligands, rather we have rank order potencies (EC50 values) of a variety of agonist ligands at each of three LPA receptors. Fig. 9 . Effect of VPC-12249 and OMPT on blood pressure and heart rate. Mice were administered intraperitoneal vehicle, VPC-12249
, or VPC-12249 ϩ OMPT every 2 h, and blood pressure (A) and heart rate (B) were measured at baseline before injection, 30 and 60 min after each injection. There was no significant difference between groups at each of the time points. SE were omitted for clarity; n ϭ 4 for each group. ischemic injury is known to lead to metabolism of membrane phospholipids in the heart (28), brain (26) , and liver (3) . The recent discovery of a lysophospholipid-preferring phospholipase D (lysoPLD), autotaxin (31) [also known as ectonucleotide phosphodiesterase pyrophophatase (ENPP) type 2], suggests that LPC is a direct precursor of LPA. Interestingly, an isotype of this enzyme, gp130 RB13-6 (ENPP-3) (29) , which also exhibits lysoPLD activity (Lynch KR, unpublished observations), is highly expressed in the mouse kidney (Okusa MD, unpublished observations). Investigations of the regulation and of this enzyme and the effect of its blockade on I/R injury are active areas of investigation in our laboratories.
The mechanism for protection is not known as multiple factors are known to participate in I/R injury. Inflammatory infiltration appears to play an important role in the pathogenesis of I/R injury (23, 30) . LPA participates in the inflammatory process by acting as a chemoattractant, by activating monocytes (6, 17) , and by increasing tissue inflammatory cell infiltration (11) . Agents that reduce inflammatory cell infiltration have reduced renal I/R injury. Both biochemical measurements of MPO and histological staining of neutrophils determined that VPC-12249 reduced leukocyte infiltration. This may lead to a decrease in inflammation, leukocyte-induced stasis of the medullary circulation, and reduce renal I/R injury. Whether a direct effect of VPC-12249 on proximal tubules or inflammatory cells mediates this protective effect is not known.
Second, our results suggest functions for two LPA receptors. LPA evokes a bewildering variety of responses when applied to cells in culture, but heretofore receptor antagonists and selective agonists have not been available to assign these various responses to individual receptors. Although the tool compounds that we used in this study are imperfect, their activities do suggest assignment of opposing activities to the LPA 2 and LPA 3 receptors. The LPA 2 receptor, which is occupied at lower LPA concentrations, exerts a protective (perhaps antiapoptotic) effect, whereas the LPA 3 receptor, which is occupied only when the LPA 2 site is saturated, is injurious, perhaps by sending a proapoptotic signal. Thus the evolution of a LPA receptor type with a distinctly lower affinity for LPA (i.e., the LPA 3 receptor) might be explained in that it is a sensor to countermand the signals sent through the higher-affinity LPA receptors (i.e., LPA 1 and LPA 2 ) when LPA levels rise above a certain threshold. It will be interesting to learn whether this bimodal action is operative in other pathologies such as cancer, where the opposite effect of LPA (proapoptosis) is desirable.
Third and finally, the activity of our LPA-receptor antagonist, VPC-12249, in preventing renal I/R injury in the mouse model suggests the LPA 3 receptor as a therapeutic target for an important set of pathologies. We are particularly encouraged by the ability of VPC-12249 to remain efficacious in preventing ischemic injury even when administered 30 min after the start of reperfusion. If verified, LPA receptor blockers might include drugs that would be useful not only prophylactically (i.e., abdominal surgery) but also reactively (i.e., trauma). Despite the development in animals of new compounds for the treatment and prevention of acute renal failure, results in human studies have been disappointing. There are many reasons for this observation including severity of illness of humans in acute renal failure studies, lack of sensitive markers of renal function, and the design of clinical trials. Certainly, major emphasis is now placed on the design of clinical trials and new early markers of acute renal failure. This effort should lead to better trial design, and we believe that innovative compounds such as VPC-12249 could lead to improved renal protection from ischemia injury in humans.
